2[3]Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant, 2003,18(9): 1899
3[4]Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis, 2003,187(11): 1801
4[5]Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood,2003,101(7): 2686
5[6]Lau GK, Nanji A, Hou J, et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat,2002, 9(4): 280
6[8]Jordan SC, Tyan DB, Stablein DM, et al. Evaluation of intravenous immunoglobulin (IVIg) as an agent to lower allosensitization and improve transplantation in highly-sensitized adult ESRD patients: report of the NIH IG02 trial (abstract 1554). American Transplant Congress 2003. Washington, DC, 2003
7[9]Bunchman TE, Parekh RS, Kershaw DB, et al. Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient. Clin Transplant,1997,11(6):604
8[10]Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with highdose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation, 2001,71(1):53
9[11]Rocha PN, Butterly DW, Greenberg A, et al. Benefcial efect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation,2003,75(9): 1490
10[12]Zidovec Lepej S, Vince A, Dakovic Rode O, et al. Increased numbers of CD38 molecules on bright CD8+ T lymphocytes in infectious mononucleosis caused by Epstein-Barr virus infection. Clin Exp Immunol,2003,133(3): 384
